Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR3273)
Drug Name
Paritaprevir
Synonyms
(2R,6S,13aS,14aR,16aS,Z)-N-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide; ABT 450; ABT-450; ABT450; CHEMBL3391662; EX-A2278; OU2YM37K86; Paritaprevir; Paritaprevir [USAN:INN]; Paritaprevir(ABT-450); Paritaprevir(Veruprevir ABT-450); SCHEMBL3069964; UNII-OU2YM37K86; Veruprevir; Veruprevir [INN]; Veruprevir anhydrous
Indication Hepatitis C virus infection [ICD11: 1E50-1E51] Phase 2 [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 765.886 Topological Polar Surface Area 198
Heavy Atom Count 55 Rotatable Bond Count 7
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 10
Cross-matching ID
PubChem CID
45110509
CAS Number
1216941-48-8
Formula
C40H43N7O7S
Canonical SMILES
CC1=NC=C(N=C1)C(=O)NC2CCCCCC=CC3CC3(NC(=O)C4CC(CN4C2=O)OC5=NC6=CC=CC=C6C7=CC=CC=C75)C(=O)NS(=O)(=O)C8CC8
InChI
InChI=1S/C40H43N7O7S/c1-24-21-42-33(22-41-24)35(48)43-32-16-6-4-2-3-5-11-25-20-40(25,39(51)46-55(52,53)27-17-18-27)45-36(49)34-19-26(23-47(34)38(32)50)54-37-30-14-8-7-12-28(30)29-13-9-10-15-31(29)44-37/h5,7-15,21-22,25-27,32,34H,2-4,6,16-20,23H2,1H3,(H,43,48)(H,45,49)(H,46,51)/b11-5-/t25-,26-,32+,34+,40-/m1/s1
InChIKey
UAUIUKWPKRJZJV-QPLHLKROSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
AC-623 DM005620
122831
Hydrolysis - Hydrolysis 1 [3]
Paritaprevir Metabolite M14 DM018427 N. A. Multi-steps Reaction - Oxidation; hydrolysis 1 [3]
Paritaprevir Metabolite M16 DM018426 N. A. Multi-steps Reaction - Oxidation; hydrolysis 1 [3]
Paritaprevir Metabolite M2 DM018424 N. A. Oxidation - Oxidation 1 [3]
Paritaprevir Metabolite M22 DM018428 N. A. Multi-steps Reaction - Oxidation; hydrolysis 1 [3]
Paritaprevir Metabolite M24 DM018425 N. A. Multi-steps Reaction - Oxidation& conjugation 1 [3]
Paritaprevir Metabolite M25 DM018423 N. A. Hydrolysis - Hydrolysis 1 [3]
Paritaprevir Metabolite M29 DM016285
68494544
Hydrolysis - Hydrolysis 1 [3]
Paritaprevir Metabolite M6 DM018420 N. A. Oxidation - Oxidation 1 [3]
Paritaprevir Metabolite M26 DM018422 N. A. Hydrolysis - Hydrolysis 2 [3]
Paritaprevir Metabolite M3 DM018421 N. A. Oxidation - Oxidation 2 [3]
⏷ Show the Full List of 11  DM(s)
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR010436 Paritaprevir Paritaprevir Metabolite M6 Oxidation - Oxidation CYP3A4 [3]
MR010438 Paritaprevir Paritaprevir Metabolite M29 Hydrolysis - Hydrolysis Unclear [3]
MR010440 Paritaprevir Paritaprevir Metabolite M25 Hydrolysis - Hydrolysis Unclear [3]
MR010442 Paritaprevir Paritaprevir Metabolite M2 Oxidation - Oxidation CYP3A4 [3]
MR010443 Paritaprevir Paritaprevir Metabolite M24 Multi-steps Reaction - Oxidation& conjugation CYP3A4 [3]
MR010444 Paritaprevir Paritaprevir Metabolite M13 Hydrolysis - Hydrolysis Unclear [3]
MR010445 Paritaprevir Paritaprevir Metabolite M16 Multi-steps Reaction - Oxidation; hydrolysis Unclear [3]
MR010446 Paritaprevir Paritaprevir Metabolite M14 Multi-steps Reaction - Oxidation; hydrolysis Unclear [3]
MR010447 Paritaprevir Paritaprevir Metabolite M22 Multi-steps Reaction - Oxidation; hydrolysis Unclear [3]
MR010441 Paritaprevir Metabolite M25 Paritaprevir Metabolite M26 Hydrolysis - Hydrolysis Unclear [3]
MR010439 Paritaprevir Metabolite M29 Paritaprevir Metabolite M26 Hydrolysis - Hydrolysis Unclear [3]
MR010437 Paritaprevir Metabolite M6 Paritaprevir Metabolite M3 Oxidation - Oxidation CYP3A4 [3]
⏷ Show the Full List of 12 MR(s)
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[2]
Cytochrome P450 3A5 (CYP3A5) DME0012 Homo sapiens
CP3A5_HUMAN
1.14.14.1
[2]
References
1 ClinicalTrials.gov (NCT01458535) A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Nave Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)
2 Main protease inhibitors and drug surface hotspots for the treatment of COVID-19: A drug repurposing and molecular docking approach
3 Metabolism and Disposition of the Hepatitis C Protease Inhibitor Paritaprevir in Humans

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.